NeuroPace (NPCE) Short term Debt (2020 - 2021)
NeuroPace (NPCE) recorded quarterly Short term Debt of $3.6 million in Q1 2021, up 75.72% quarter-over-quarter from $2.0 million in Q4 2020.
NeuroPace (NPCE) Short term Debt (2020 - 2021) Analysis & Trends
NeuroPace's Short term Debt history runs 2 years deep, the most recent figure standing at $3.6 million for Q1 2021.
- In Q1 2021, Short term Debt changed N/A year-over-year to $3.6 million; the TTM figure through Mar 2021 stood at $3.6 million (changed N/A YoY), while the FY2020 annual figure was $2.0 million, changed N/A from the prior year.
- Short term Debt was $3.6 million for Q1 2021 at NeuroPace, up from $2.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $3.6 million in Q1 2021 to a low of $2.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | NeuroPace | 527.50 Mn | 473.52 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 3.59 Mn |
| Dec 31, 2020 | 2.04 Mn |